1-7 of 7
Joachim Drevs
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I dose-escalation and pharmacokinetic (PK) study of a (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH) in patients with advanced cancers

Daniela Gmehling, Michael Medinger, Felix Kratz, Klaus Mross, Brigitte Haering, Clemens Unger, Joachim Drevs
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 939.
Published: 01 May 2005
View article titled, Phase I dose-escalation and pharmacokinetic (PK) study of a (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH) in patients with advanced cancers
Journal Articles

Development of albumin-binding prodrugs that are cleaved by prostate-specific antigen

Da-Eun Chung, Ahmed M. Mansour, Joachim Drevs, Clemens Unger, Iduna Fichtner, Felix Kratz
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 333.
Published: 01 May 2005
View article titled, Development of albumin-binding prodrugs that are cleaved by prostate-specific antigen
Journal Articles

Effect of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, on primary tumor growth, metastasis and vessel density in murine renal cell carcinoma

Joachim Drevs, Norbert Esser, Stephen R. Wedge, Anderson J. Ryan, Donald J. Ogilvie, Dieter Marme
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 1051–1052.
Published: 01 April 2004
View article titled, Effect of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, on primary tumor growth, metastasis and vessel density in murine renal cell carcinoma
Journal Articles

A New Approach for the Treatment of Malignant Melanoma: Enhanced Antitumor Efficacy of an Albumin-binding Doxorubicin Prodrug That Is Cleaved by Matrix Metalloproteinase 2

Ahmed M. Mansour, Joachim Drevs, Norbert Esser, Farid M. Hamada, Osama A. Badary, Clemens Unger, Iduna Fichtner, Felix Kratz
Journal: Cancer Research
Cancer Res (2003) 63 (14): 4062–4066.
Published: 21 July 2003
View article titled, A New Approach for the Treatment of Malignant Melanoma: Enhanced Antitumor Efficacy of an Albumin-binding Doxorubicin Prodrug That Is Cleaved by Matrix Metalloproteinase 2
Open the PDF for A New Approach for the Treatment of Malignant Melanoma: Enhanced Antitumor Efficacy of an Albumin-binding Doxorubicin Prodrug That Is Cleaved by Matrix Metalloproteinase 2 in another window
Journal Articles

PTK787/ZK 222584, a Specific Vascular Endothelial Growth Factor-Receptor Tyrosine Kinase Inhibitor, Affects the Anatomy of the Tumor Vascular Bed and the Functional Vascular Properties as Detected by Dynamic Enhanced Magnetic Resonance Imaging

Joachim Drevs, Ralph Müller-Driver, Christine Wittig, Stefan Fuxius, Norbert Esser, Harald Hugenschmidt, Moritz A. Konerding, Peter R. Allegrini, Jeanette Wood, Jürgen Hennig, Clemens Unger, Dieter Marmé
Journal: Cancer Research
Cancer Res (2002) 62 (14): 4015–4022.
Published: 15 July 2002
View article titled, PTK787/ZK 222584, a Specific Vascular Endothelial Growth Factor-Receptor Tyrosine Kinase Inhibitor, Affects the Anatomy of the Tumor Vascular Bed and the Functional Vascular Properties as Detected by Dynamic Enhanced Magnetic Resonance Imaging
Open the PDF for PTK787/ZK 222584, a Specific Vascular Endothelial Growth Factor-Receptor Tyrosine Kinase Inhibitor, Affects the Anatomy of the Tumor Vascular Bed and the Functional Vascular Properties as Detected by Dynamic Enhanced Magnetic Resonance Imaging in another window
Journal Articles

Effects of PTK787/ZK 222584, a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, on Primary Tumor, Metastasis, Vessel Density, and Blood Flow in a Murine Renal Cell Carcinoma Model

Joachim Drevs, Inga Hofmann, Harald Hugenschmidt, Christine Wittig, Helmut Madjar, Marianne Müller, Jeanette Wood, Georg Martiny-Baron, Clemens Unger, Dieter Marmé
Journal: Cancer Research
Cancer Res (2000) 60 (17): 4819–4824.
Published: 01 September 2000
View article titled, Effects of PTK787/ZK 222584, a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, on Primary Tumor, Metastasis, Vessel Density, and Blood Flow in a Murine Renal Cell Carcinoma Model
Open the PDF for Effects of PTK787/ZK 222584, a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, on Primary Tumor, Metastasis, Vessel Density, and Blood Flow in a Murine Renal Cell Carcinoma Model in another window
Journal Articles

PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration

Jeanette M. Wood, Guido Bold, Elizabeth Buchdunger, Robert Cozens, Stefano Ferrari, Jörg Frei, Francesco Hofmann, Jürgen Mestan, Helmut Mett, Terence O’Reilly, Elke Persohn, Johannes Rösel, Christian Schnell, David Stover, Andreas Theuer, Harry Towbin, Fritz Wenger, Kathie Woods-Cook, Andreas Menrad, Gerhard Siemeister, Michael Schirner, Karl-Heinz Thierauch, Martin R. Schneider, Joachim Drevs, Georg Martiny-Baron, Frank Totzke, Dieter Marmé
Journal: Cancer Research
Cancer Res (2000) 60 (8): 2178–2189.
Published: 01 April 2000
View article titled, PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration
Open the PDF for PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration in another window